Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Open-Label, Active-Controlled, Non-Inferiority Phase 3 Study to Evaluate the Efficacy and Safety of Human Growth Hormone Injection (Sinotropin AQ) for the Treatment of Children With Idiopathic Short Stature (ISS)

NCT07815626 is registered in ClinicalTrials.gov with Zhongshan Sansure Hygene Biomedicine Co., Ltd. as lead sponsor.

NCT NCT07815626
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07815626 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Open-Label, Active-Controlled, Non-Inferiority Phase 3 Study to Evaluate the Efficacy and Safety of Human Growth Hormone Injection (Sinotropin AQ) for the Treatment of Children With Idiopathic Short Stature (ISS)
Lead sponsor
Zhongshan Sansure Hygene Biomedicine Co., Ltd.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
February 28, 2029
Enrollment
240 (estimated)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic short stature (iss)